A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
Clinical trial NCT06115642 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06115642
- Sponsor
- Shanghai Henlius Biotech
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-24
- Primary completion
- 2026-06-30
- Enrollment
- 367
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.